FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 248 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC October 6, 2020 Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC June 6, 2025 Fear July 26, 2022 Cancer services during COVID-19: 40,000 fewer people starting treatment February 2, 2021 Load more HOT NEWS Black In Cancer – That Cancer Conversation Reflecting On My Time As the Cancer.Net Editor in Chief How our global activity is tackling cancer prevention in low- and... Prostate Cancer Genomics in Racial Minority Groups
